Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rivière I[au]:

Therapeutic T cell engineering. Sadelain M et al. Nature. (2017)

The basic principles of chimeric antigen receptor design. Sadelain M et al. Cancer Discov. (2013)

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Rivière I et al. Mol Ther. (2017)

Search results

Items: 1 to 50 of 91

1.

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.

Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ.

Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.

PMID:
31262783
2.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ.

Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.

PMID:
31113804
3.

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ.

JCI Insight. 2019 Apr 2;5. pii: 122627. doi: 10.1172/jci.insight.122627.

4.

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.

Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, Li Z, Cunanan KM, Huse M, Hendrickson RC, Wang X, Rivière I, Sadelain M.

Nature. 2019 Apr;568(7750):112-116. doi: 10.1038/s41586-019-1054-1. Epub 2019 Mar 27.

PMID:
30918399
5.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.

Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ.

Sci Transl Med. 2019 Mar 27;11(485). pii: eaau7746. doi: 10.1126/scitranslmed.aau7746.

PMID:
30918115
6.

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Aug 17;10:371-378. doi: 10.1016/j.omtm.2018.08.006. eCollection 2018 Sep 21.

7.

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH.

Mol Ther. 2018 Aug 1;26(8):1896-1905. doi: 10.1016/j.ymthe.2018.05.018. Epub 2018 Jun 15.

8.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.

9.

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

Smith EL, Staehr M, Masakayan R, Tatake IJ, Purdon TJ, Wang X, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Riviere I, Liu C, Brentjens RJ.

Mol Ther. 2018 Jun 6;26(6):1447-1456. doi: 10.1016/j.ymthe.2018.03.016. Epub 2018 Mar 28.

10.

Gene Therapy and Genome Editing.

Boulad F, Mansilla-Soto J, Cabriolu A, Rivière I, Sadelain M.

Hematol Oncol Clin North Am. 2018 Apr;32(2):329-342. doi: 10.1016/j.hoc.2017.11.007. Epub 2018 Jan 9. Review. Erratum in: Hematol Oncol Clin North Am. 2018 Jun;32(3):xiii.

PMID:
29458735
11.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M.

N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.

12.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.

Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ.

Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18. No abstract available.

13.

Therapeutic T cell engineering.

Sadelain M, Rivière I, Riddell S.

Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Review.

14.

Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

Wang X, Rivière I.

Mol Ther Methods Clin Dev. 2017 Mar 18;5:96-105. doi: 10.1016/j.omtm.2017.03.003. eCollection 2017 Jun 16. Review.

15.

Perspectives on Manufacturing of High-Quality Cell Therapies.

Rivière I, Roy K.

Mol Ther. 2017 May 3;25(5):1067-1068. doi: 10.1016/j.ymthe.2017.04.010. Epub 2017 Apr 24. No abstract available.

16.

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Rivière I, Sadelain M.

Mol Ther. 2017 May 3;25(5):1117-1124. doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26. Review.

17.

Showcasing Clinical Development and Production of Cellular Therapies.

Levine BL, Fesnak AD, Riviere I.

Mol Ther. 2017 Apr 5;25(4):827-828. doi: 10.1016/j.ymthe.2017.03.007. Epub 2017 Mar 22. No abstract available.

18.

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.

Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M.

Mol Ther Oncolytics. 2017 Jan 11;3:1-9. doi: 10.1038/mto.2016.23. eCollection 2016.

19.

Clinical manufacturing of CAR T cells: foundation of a promising therapy.

Wang X, Rivière I.

Mol Ther Oncolytics. 2016 Jun 15;3:16015. doi: 10.1038/mto.2016.15. eCollection 2016. Review.

20.

Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.

Hasan AN, Selvakumar A, Shabrova E, Liu XR, Afridi F, Heller G, Riviere I, Sadelain M, Dupont B, O'Reilly RJ.

Clin Exp Immunol. 2016 Nov;186(2):249-265. doi: 10.1111/cei.12816. Epub 2016 Aug 31.

21.

Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects.

Mansilla-Soto J, Riviere I, Boulad F, Sadelain M.

Hum Gene Ther. 2016 Apr;27(4):295-304. doi: 10.1089/hum.2016.037. Review.

22.

Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.

Karponi G, Psatha N, Lederer CW, Adair JE, Zervou F, Zogas N, Kleanthous M, Tsatalas C, Anagnostopoulos A, Sadelain M, Rivière I, Stamatoyannopoulos G, Yannaki E.

Blood. 2015 Jul 30;126(5):616-9. doi: 10.1182/blood-2015-03-629618. Epub 2015 Jun 18.

23.

CD19 CAR Therapy for Acute Lymphoblastic Leukemia.

Sadelain M, Brentjens R, Rivière I, Park J.

Am Soc Clin Oncol Educ Book. 2015:e360-3. doi: 10.14694/EdBook_AM.2015.35.e360. Review.

24.

New cell sources for T cell engineering and adoptive immunotherapy.

Themeli M, Rivière I, Sadelain M.

Cell Stem Cell. 2015 Apr 2;16(4):357-66. doi: 10.1016/j.stem.2015.03.011. Review.

25.

Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.

Wang X, Olszewska M, Qu J, Wasielewska T, Bartido S, Hermetet G, Sadelain M, Rivière I.

J Immunother. 2015 Apr;38(3):127-35. doi: 10.1097/CJI.0000000000000072.

26.

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Wang X, Rivière I.

Cancer Gene Ther. 2015 Mar;22(2):85-94. doi: 10.1038/cgt.2014.81. Epub 2015 Feb 27. Review.

27.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

28.

Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.

Boulad F, Wang X, Qu J, Taylor C, Ferro L, Karponi G, Bartido S, Giardina P, Heller G, Prockop SE, Maggio A, Sadelain M, Rivière I.

Blood. 2014 Mar 6;123(10):1483-6. doi: 10.1182/blood-2013-06-507178. Epub 2014 Jan 15.

29.

CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.

Tsukahara T, Ohmine K, Yamamoto C, Uchibori R, Ido H, Teruya T, Urabe M, Mizukami H, Kume A, Nakamura M, Mineno J, Takesako K, Riviere I, Sadelain M, Brentjens R, Ozawa K.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):84-9. doi: 10.1016/j.bbrc.2013.07.030. Epub 2013 Jul 17.

30.

The basic principles of chimeric antigen receptor design.

Sadelain M, Brentjens R, Rivière I.

Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2. Review.

31.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

32.

How do CARs work?: Early insights from recent clinical studies targeting CD19.

Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M.

Oncoimmunology. 2012 Dec 1;1(9):1577-1583.

33.

Hematopoietic stem cell engineering at a crossroads.

Rivière I, Dunbar CE, Sadelain M.

Blood. 2012 Feb 2;119(5):1107-16. doi: 10.1182/blood-2011-09-349993. Epub 2011 Nov 17. Review.

34.

Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγ mice.

Ghinassi B, Ferro L, Masiello F, Tirelli V, Sanchez M, Migliaccio G, Whitsett C, Kachala S, Riviere I, Sadelain M, Migliaccio AR.

Stem Cells Int. 2011;2011:673752. doi: 10.4061/2011/673752. Epub 2011 Aug 16.

35.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

36.

Genetic strategies for the treatment of sickle cell anaemia.

Mansilla-Soto J, Rivière I, Sadelain M.

Br J Haematol. 2011 Sep;154(6):715-27. doi: 10.1111/j.1365-2141.2011.08773.x. Epub 2011 Jun 28. Review.

PMID:
21707580
37.

Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells.

Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M.

Nat Biotechnol. 2011 Jan;29(1):73-8. doi: 10.1038/nbt.1717. Epub 2010 Dec 12.

38.

Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.

Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ.

J Vet Intern Med. 2011 Jan-Feb;25(1):94-9. doi: 10.1111/j.1939-1676.2010.0627.x. Epub 2010 Dec 8.

39.

Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia.

Sadelain M, Rivière I, Wang X, Boulad F, Prockop S, Giardina P, Maggio A, Galanello R, Locatelli F, Yannaki E.

Ann N Y Acad Sci. 2010 Aug;1202:52-8. doi: 10.1111/j.1749-6632.2010.05597.x.

PMID:
20712772
40.

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M.

Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31. No abstract available.

41.

Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies.

Hasan AN, Selvakumar A, Doubrovina E, Riviere I, Sadelain MW, O'Reilly RJ.

Discov Med. 2009 Dec;8(43):210-8. Review.

42.

Gene therapy for homozygous beta-thalassemia. Is it a reality?

Boulad F, Rivière I, Sadelain M.

Hemoglobin. 2009;33 Suppl 1:S188-96. doi: 10.3109/03630260903351866.

PMID:
20001625
43.

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M.

Mol Ther. 2010 Feb;18(2):413-20. doi: 10.1038/mt.2009.210. Epub 2009 Sep 22.

44.

Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media.

Ghani K, Wang X, de Campos-Lima PO, Olszewska M, Kamen A, Rivière I, Caruso M.

Hum Gene Ther. 2009 Sep;20(9):966-74. doi: 10.1089/hum.2009.001.

45.

The promise and potential pitfalls of chimeric antigen receptors.

Sadelain M, Brentjens R, Rivière I.

Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Review.

46.

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I.

J Immunother. 2009 Feb-Mar;32(2):169-80. doi: 10.1097/CJI.0b013e318194a6e8.

47.
48.

Stem cell engineering for the treatment of severe hemoglobinopathies.

Sadelain M, Boulad F, Lisowki L, Moi P, Riviere I.

Curr Mol Med. 2008 Nov;8(7):690-7. Review.

PMID:
18991654
49.

Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gamma-retrovirus-encoded hsvtk suicide genes.

Wang X, Olszewska M, Capacio V, Stefanski J, Przybylowski M, Samakoglu S, Chang AH, Sadelain M, Rivière I.

Gene Ther. 2008 Nov;15(21):1454-9. doi: 10.1038/gt.2008.103. Epub 2008 Jun 19.

50.

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.

Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zúñiga-Pflücker JC, Lu C, van den Brink MR.

Nat Biotechnol. 2008 Apr;26(4):453-61. doi: 10.1038/nbt1395. Epub 2008 Mar 30.

Supplemental Content

Loading ...
Support Center